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infections, such as those affecting the gastroin-
testinal tract, that fuel HIV replication.
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The authors reply: Our study was a proof-of-
concept trial and so did not allow prediction of 
the effect of HSV suppressive therapy as a public 
health intervention to prevent the transmission 
of HIV. Available data regarding resistance to acy-
clovir are reassuring. The occurrence of acyclovir-
resistant HSV-2 strains in HIV-infected patients 
(4 to 7%) has not increased during the past two 
decades in Western countries, despite the fre-
quent use of acyclovir and valacyclovir.1 Instead, 
resistance to acyclovir could be declining, since 
the use of highly active antiretroviral therapy has 
become widespread.2 When such resistance oc-
curs, it is not predictive of clinical failure.3 In 
addition, the occurrence of genital ulceration dur-
ing the course of HSV suppressive therapy does 
not necessarily mean that the causative strain is 
resistant to acyclovir. We agree that in the absence 
of second-line therapy in resource-constrained 
countries (and considering the paucity of data 
available to date), the importance of resistance to 
acyclovir should be investigated further. However, 
even if such resistance is confirmed, it is unlikely 
to counterbalance the potential positive effect of 
HSV suppressive therapy on HIV-1 disease pro-
gression and transmission.
The HIV-1 plasma viral load in the placebo 
group increased slightly during our study, but we 
doubt this rise was due to HIV-unrelated gastro-
intestinal diseases. Several women reported hav-
1.
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ing more than one symptom, so the P value cal-
culated by Dr. Eisenhut needs modification. In 
fact, the proportion of women who reported at 
least one gastrointestinal symptom tended to be 
higher in the placebo group (38.2%) than in the 
valacyclovir group (25.0%) but without reaching 
statistical significance (P = 0.10). Valacyclovir and 
acyclovir have been used for decades with a safety 
profile similar to that of placebo.4 The hypothesis 
by Brenchley et al.5 that a sustained systemic im-
mune activation is fueled by intestinal bacteria 
through a translocation mechanism is based on 
the commensal enteric f lora and not on patho-
gens. It is unlikely that this mechanism could be 
altered or enhanced by the intake of valacyclovir. 
It should also be noted that our primary outcome 
was genital HIV viral load, and there was little 
difference in this outcome in the placebo group 
before randomization and after randomization 
(mean number of log10 copies per milliliter, 2.97 
and 3.02, respectively).
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Coronary Microvascular Dysfunction
To the Editor: Camici and Crea (Feb. 22 issue)1 
review the different causes and mechanisms of 
coronary microvascular dysfunction. However, 
coronary microvascular dysfunction due to aging 
deserves further comment. Age is a recognized 
risk factor for cardiovascular disease, and senes-
cence is associated with morphologic and func-
tional changes in the coronary microvasculature.2 
Studies in animals have shown that coronary flow 
reserve and the endothelium-dependent dilatation 
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on April 12, 2019. For personal use only. No other uses without permission. 
 Copyright © 2007 Massachusetts Medical Society. All rights reserved. 
correspondence
n engl j med 356;22 www.nejm.org may 31, 2007 2325
of the resistance arteries decrease with age.3 It has 
been suggested that endothelium-dependent dila-
tation of the resistance coronary arteries evoked by 
acetylcholine may decrease with age in humans.4
The mechanisms underlying the age-associat-
ed reduction in the ability of the coronary micro-
vasculature to dilate in response to acetylcholine 
are controversial. With advancing age, nitrous 
oxide–dependent mechanical and agonist-medi-
ated endothelial vasodilatation is reduced in 
humans and animals.5 Coronary microvascular 
dysfunction due to aging should not be underes-
timated. Although pharmacologic treatment has 
been shown to restore coronary blood reserve in 
endothelial dysfunction due to aging, its effect on 
the clinical outcome remains to be determined.
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The Authors Reply: We agree with Duran and 
Taffet that coronary microvascular function chang-
es significantly with aging. Indeed, we stated, 
“In healthy persons, however, coronary f low re-
serve varies according to age and sex. Therefore, 
it is essential to compare data on coronary f low 
reserve in patients with data obtained in age-
matched and sex-matched control subjects.” Using 
positron-emission tomography, Uren et al.1 and 
Chareonthaitawee et al.2 have shown that resting 
and hyperemic myocardial blood flow remain un-
changed in persons up to 60 years of age. After 
60 years of age, there is a significant increase in 
resting myocardial blood flow, associated with 
an increase in systolic blood pressure. After 70 
years of age, there is a significant reduction in 
hyperemic myocardial blood flow and in coronary 
flow reserve. There are probably multiple causes 
of these age-related changes, and they remain in-
completely understood.
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Perioperative Stroke
To the Editor: In his review of perioperative 
stroke, Selim (Feb. 15 issue)1 states that regional 
anesthesia may pose less risk of perioperative 
complications than general anesthesia and that 
“isoflurane and thiopentone may provide neuro-
protection.” However, the references that he cites2,3 
do not provide support for these contentions. 
Breen and Park’s2 review of the literature showed 
that no conclusions could be drawn about the 
risk of stroke associated with general as compared 
with regional anesthesia for carotid endarterec-
tomy. In fact, the results of the randomized tri-
als reviewed indicated that postoperative hypo-
tension was more likely after regional anesthesia. 
The differences that have been identified may not 
have a great clinical impact and require further 
study.
Turner et al.3 reviewed the literature on agents 
for induction of general anesthesia and conclude 
that thiopental, propofol, and etomidate have 
similar effects on intracranial pressure, cerebral 
blood flow, and cerebral oxygen consumption, 
so the selection of an agent should be based on 
other considerations. They did not discuss isoflu-
rane. The most one can conclude from the extant 
literature is that there are a number of hypotheses 
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